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Abstract
Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-
E) are associated with increased mortality. Outcome differences due to various species of
ESBL-E or ESBL genotypes are not well investigated. We conducted a cohort study to
assess risk factors for mortality in cases of ESBL-E bacteremia (K. pneumoniae or E. coli)
and the risk factors for sepsis with organ failure. All consecutive patients of our institution
from 2008 to 2011 with bacteremia due to ESBL-E were included. Basic epidemiological
data, underlying comorbidities, origin of bacteremia, severity of sepsis and delay of appro-
priate anti-infective treatment were collected. Isolates were PCR-screened for the presence
of ESBL genes and plasmid-mediated AmpC β-lactamases. Cox proportional hazard
regression on mortality and multivariable logistic regression on risk factors for sepsis with
organ failure was conducted. 219 cases were included in the analysis: 73.1% due to E. coli,
26.9% due to K. pneumoniae. There was no significant difference in hospital mortality
(ESBL-E. coli, 23.8% vs. ESBL-K. pneumoniae 27.1%, p = 0.724). However, the risk of
sepsis with organ failure was associated in cases of K. pneumoniae bacteremia (OR 4.5,
p<0.001) and patients with liver disease (OR 3.4, p = 0.004) or renal disease (OR 6.8,
p<0.001). We found significant differences in clinical presentation of ESBL-E bacteremia
due to K. pneumoniae compared to E. coli. As K. pneumoniae cases showed a more serious
clinical presentation as E. coli cases and were associated with different risk factors, treat-
ment and prevention strategies should be adjusted accordingly.
PLOS ONE | DOI:10.1371/journal.pone.0158039 July 21, 2016 1 / 13
a11111
OPEN ACCESS
Citation: Sakellariou C, Gürntke S, Steinmetz I,
Kohler C, Pfeifer Y, Gastmeier P, et al. (2016) Sepsis
Caused by Extended-Spectrum Beta-Lactamase
(ESBL)-Positive K. pneumoniae and E. coli:
Comparison of Severity of Sepsis, Delay of Anti-
Infective Therapy and ESBL Genotype. PLoS ONE
11(7): e0158039. doi:10.1371/journal.pone.0158039
Editor:W.C. Yam, The University of Hong Kong,
CHINA
Received: January 20, 2016
Accepted: June 9, 2016
Published: July 21, 2016
Copyright: © 2016 Sakellariou et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was funded by 01KI1013H;
http://www.reset-verbund.de/, Federal Ministry of
Education and Research, to RL PG. The funders had
no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E)
are associated with impaired outcome compared to infections with susceptible pathogens [1–
3]. Former studies on ESBL-E bacteremia proved that a delay of adequate antimicrobial che-
motherapy can be an important factor on mortality [1, 2, 4]. This effect seems to be the most
evident in cases of septic shock or organ failure [5]. This is even more important since there is
evidence that infections due to K. pneumoniae are associated with a worse course compared to
other Enterobacteriaceae [4, 6, 7]. However, studies concerning ESBL-E infections often do not
differentiate between the infecting species. There are only few studies comparing outcome
parameter of different Enterobacteriaceae [4, 6, 8–10]. To analyze the effect of the different
ESBL-E species on mortality and on the clinical presentation, we conducted a cohort study
comparing cases of ESBL-positive K. pneumoniae- and E. coli bacteremia including data on the
timing of their antimicrobial treatment.
Methods
Study design
We conducted a retrospective cohort study on patients with bacteremia due to ESBL-E. The
setting of this study was the Charité University Hospital in Berlin, Germany, a tertiary care uni-
versity hospital with over 120,000 admissions per year. Previously, our ethics committee
approved the study without informed consent. The patient data based on secondary clinical
information. The biological material was obtained clinically and analyzed by a separate institu-
tion after anonymization in our institution (reference number EA4/031/11). Parts of the study
have been published in different analyses including differing data sets [10, 11].
All inpatients with ESBL-E bacteremia (E. coli or K. pneumoniae) diagnosed between Janu-
ary 1st, 2008 and December 31st 2011 were included. The bacteremia was classified as hospital
onset if a positive blood culture was collected after the third hospital day. In case of more than
one cultured organism in the first positive blood culture, the episode was defined as polymicro-
bial bacteremia. If the patient showed multiple subsequent positive blood cultures, the first pos-
itive blood culture lead to the allocation to one of the two pathogens and this episode was
included in the analysis. Underlying comorbidities were assessed according to the method by
Charlson et al. [12]. The comorbidities were collected using the patients’ ICD-10 codes and
grouped for the calculation of the Charlson comorbidity index (CCI) according to the method
by Thygesen et al. [13].
Further clinical parameters were collected by analysis of the patients’ files. To assess the
origin of ESBL bacteremia we collected data on earlier infections during the analyzed hospital
stay. These infections were due to same ESBL-positive organisms as the corresponding bacter-
emia episode and at maximum 14 days prior to the bacteremia onset. The infections were
assessed according to the CDC definitions [14]. Primary bacteremia was defined as central
venous catheter (CVC)<48h prior to the bacteremia onset without presence of another
ESBL-E infection. Mortality was defined as in-hospital mortality and ESBL colonization was
assessed as colonization with ESBL-E prior to the bacteremia episode at any site. Sepsis, severe
sepsis, and septic shock were defined according to the definitions of the consensus conference
of the American College of Chest Physicians and the Society of Critical Care Medicine which
also find application in Germany [15, 16]. Delay of anti-infective treatment (DAT) was
defined as initiation of effective treatment1 day after onset of bacteremia. Effective treat-
ment was defined as an antimicrobial agent the ESBL-positive organism was tested susceptible
against.
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Microbiological methods
Species identification and antimicrobial susceptibility testing was performed using the Vitek 2
automated system with interpretation and antibiogram reporting according to the CLSI stan-
dard [17]. Confirmation of ESBL production was performed by a minimum inhibitory concen-
tration dilution test on a multiwell microtiter plate. Three cephalosporins (cefotaxime,
ceftazidime, cefpodoxime) were tested alone and in combination with ESBL inhibitor clavula-
nic acid. All verification swabs were inoculated onto chrome ID ESBL agar (BioMerieux).
ESBL-positive isolates were affirmed by Double Disc Synergie Testing using 3rd generation
cephalosporins with/without clavulanic acid (Mast). Species confirmation was done by API20E
(BioMerieux). The isolates were screened for the presence of different ESBL genes (blaTEM-
type, blaSHV-type, blaCTX-M-1/2/9 group) by polymerase chain reaction (PCR) and subse-
quent sequencing [18]. If none of these ESBL genes could be identified, additional PCR tests
for the presence of plasmid-mediated AmpC β-lactamases [19] and further ESBL genes
(blaCTX-M-8-type, blaCTX-M-26-type) were performed [20]. Furthermore, basic bacterial
typing of all ESBL-positive E. coli isolates was performed by a PCR-based method for determi-
nation of the four major E. coli phylogenetic groups [21].
Statistical methods
Parameters in the univariate analysis were tested using the Wilcoxon rank sum test for contin-
uous variables and the Fisher’s exact test for categorical variables. For the analysis of factors
associated to severity of illness, the categories were transformed to a binary category as bacter-
emia (bacteremia and sepsis) vs. sepsis with organ failure (severe sepsis and septic shock). Clin-
ical parameter of E. coli- and K. pneumoniae- cases were compared using univariate analysis.
Multivariable binary logistic analysis using a stepwise forward regression was computed for the
analysis of clinical risk factors for sepsis with organ failure. We compared the clinical parame-
ter of the deceased patients and the alive discharged patients using univariate analysis. We cal-
culated adjusted hazard ratios for in-hospital death using Cox-proportional hazard regression
using a stepwise forward approach. In both multivariable analyses, parameters with p-values
<0.20 in the univariate analyses were considered in the analysis. Variables with p-values<0.05
were included and variables with p0.05 were excluded. All tests of were two tailed with a p-
value<0.05 considered to be significant. Data was analyzed using IBM SPSS Statistics Version
22.
Results
We identified altogether 243 consecutive cases of bacteremia, 177 cases due to ESBL-positive E.
coli (73.1%) and 66 cases due to K. pneumoniae (27.2%) together. No case showed both ana-
lyzed pathogens in the same blood culture. From twenty-three cases (9.9%), sufficient data was
not available and therefore excluded. The remaining 219 cases were analyzed (n = 160, 73.1%
due to E. coli and n = 59, 26.9% due to K. pneumoniae). We found an increasing risk for mor-
tality in relation to the applied definitions for severity of sepsis (Fig 1). The characteristics of
the analyzed cohort stratified by infecting organism are given in S1 Table. Patients suffering
from ESBL-positive K. pneumoniae bacteremia (ESBL-KP-Bac) were younger than the com-
pared patients with ESBL-positive E. coli bacteremia (ESBL-EC-Bac). They more often had a
secondary bacteremia due to a surgical site infection and more often an unknown source of
infection. ESBL-KP-Bac was more often associated with sepsis with organ failure. Patients
with sepsis with organ failure showed significantly reduced DAT compared to patients present-
ing with bacteremia only (Median 0 days, IQR 0;2 days vs. Median 2 days, IQR 0;3 days,
p = 0.003). Patients with ESBL-KP-Bac showed an increased mortality compared to
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ESBL-EC-Bac (27.1% vs. 23.8%) but not statistical significant. ESBL-EC-Bac however, was
more common among patients with previous urinary tract infection. The mostly used antimi-
crobial agents after infection onset were carbapenems: 71.2% (n = 156), quinolones 12.3%
(n = 27), tigecyclin 5.0% (n = 11), piperacillin-tazobactam 2.3% (n = 5) and gentamicin 2.3%
(n = 5).
Microbiology parameter
In the clinically reported antibiogram, 98.6% (n = 216) isolates were resistant to piperacillin/
tazobactam, 98.2% (n = 215) to ceftazidime, 69.4% (n = 152) to ciprofloxacin and 43.4%
(n = 95) to gentamicin. None of the included isolates was reported resistant to the carbapenems
imipenem or meropenem. Of the 219 isolates, 88.5% (n = 194) were available for further ESBL
genotype analysis; the remaining 25 were not retrievable. The distribution of the ESBL geno-
types is shown in Tables 1 and 2 with overall CTX-M-15, CTX-M-1, CTX-M-14 and SHV-5 as
most common types. One-hundred and seven isolates (55.2%) carried two or more TEM- or
SHV-type beta-lactamases. Seven isolates (3.6%) did not carry an ESBL gene. Five showed
either TEM-181, TEM-1 or SHV-1 overproduction, one was CMY-positive and one did not
show any beta-lactamase at all. The distribution pattern of the phylogenetic groups within the
analyzed 140 E. coli isolates was B2 (33.6%, n = 47), A (28.6%, n = 40), D (26.4%, n = 37) and
B1 (11.4%, n = 16).
Factors associated with sepsis with organ failure
Table 3 shows the results of the multivariable analysis on risk factors for sepsis with organ fail-
ure. The K. pneumoniae cases were associated with 4.5 times higher odds for an organ failure at
presentation. Furthermore, sepsis with organ failure was associated with liver disease (OR 3.3)
and moderate to severe renal disease (OR 6.835).
Fig 1. Severity of sepsis in relation to mortality rate.
doi:10.1371/journal.pone.0158039.g001
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Table 1. Univariate analysis of clinical parameter in patients presenting with sepsis with organ failure and bacteremia.
Parameter Bacteremia (n = 138) Sepsis with organ failure (n = 81) P-value
Age years / Age < 61 years 67 (48.6%) 42 (51.9%) 0.676
Male sex 93 (67.4%) 53 (65.4%) 0.769
Charlson comorbidity index > 6 63 (45.7%) 51 (63.0%) 0.017
In-hospital death 12 (8.7%) 42 (51.9%) <0.001
Polymicrobial bacteraemia 19 (13.8%) 10 (12.3%) 0.839
Hospital onset 74 (53.6%) 59 (72.8%) 0.006*
ESBL colonization before onset 85 (61.6%) 53 (65.4%) 0.664
Bacteraemia due to E. coli 115 (83.3%) 45 (55.6%) <0.001*
Bacteraemia due to K. pneumoniae 23 (16.7%) 36 (44.4%)
Origin of ESBL-E bacteraemia
Urinary tract infection 55 (39.9%) 20 (24.7%) 0.027*
Lower respiratory tract infection 22 (15.9%) 18 (22.2%) 0.279
Intra-abdominal infection 9 (6.5%) 13 (16.0%) 0.035*
Surgical site infection 4 (2.9%) 4 (4.9%) 0.472
Primary bacteraemia 19 (13.8%) 11 (13.6%) 1.000
Other 6 (4.3%) 2 (2.5%) 0.756
Unknown Origin 35 (25.4%) 19 (23.4%) 0.883
Severity of illness and delay of anti-infective treatment
Delayed adequate anti-infective treatment 70 (50.7%) 25 (30.9%) <0.001
ESBL Genotype
No ESBL genotype 4 (2.9%) 3 (3.7%) 0.711
CTX-M-1 30 (21.7%) 9 (11.1%) 0.066*
CTX-M-14 8 (5.8%) 6 (7.4%) 0.776
CTX-M-15 60 (43.5%) 38 (46.9%) 0.674
CTX-M-2 1 (0.7%) - 1.000
CTX-M-2/97 2 (1.4%) - 0.532
CTX-M-3 4 (2.9%) 2 (2.5%) 1.000
CTX-M-32 - 2 (2.5%) 0.136
CTX-M-55 1 (0.7%) 1 (1.2%) 1.000
CTX-M-61 1 (0.7%) - 1.000
SHV-12 2 (1.4%) - 0.532
SHV-2 1 (0.7%) - 1.000
SHV-5 4 (2.9%) 9 (11.1%) 0.018*
SHV-7 - 1 (1.2%) 0.370
TEM-12 1 (0.7%) - 1.000
TEM-52 3 (2.2%) 1 (1.2%) 1.000
Unknown (not available for genotype analysis) 16 (11.6%) 9 (11.1%) 1.000
Underlying conditions
Heart disease 16 (11.6%) 23 (28.4%) 0.003*
Vascular disease 24 (17.4%) 21 (25.9%) 0.166*
Neurologic disease 14 (10.1%) 7 (8.6%) 0.815
Chronic pulmonary disease 17 (12.3%) 19 (23.5%) 0.038*
Connective tissue disease 3 (2.2%) - 0.298
Ulcer disease 6 (4.3%) 2 (2.5%) 0.713
Liver disease 16 (11.6%) 25 (30.9%) <0.001*
Diabetes mellitus 34 (24.6%) 20 (24.7%) 1.000
Moderate to severe renal disease 44 (31.9%) 62 (76.5%) <0.001*
(Continued)
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Factors associated with in-hospital mortality (Cox-proportional hazard
analysis)
The results of the univariate analysis on in-hospital mortality are displayed in Table 2. In order
to assess the effect of the infecting organism (E. coli vs. K. pneumoniae) on mortality this
parameter was also considered in the Cox-proportional hazard regression. The deceased had
significantly higher CCIs. These patients also had significantly more often a hospital onset bac-
teremia, sepsis with organ failure, prior episodes of lower respiratory tract infection, intra-
abdominal infection or primary bacteremia, underlying heart disease, liver- or renal disease.
The survivors had more commonly a urinary tract infection prior to their bacteremia. The
results of the Cox-proportional hazard regression (Table 4) showed that sepsis with organ fail-
ure was associated with a 4.5-fold higher hazard for mortality, renal disease and liver disease
with 2.7-fold and 1.8-fold elevated hazard. The only protective factor was urinary tract infec-
tion that was associated with a hazard reduction for mortality of about 61% (HR 0.39). There
was no statistically significant difference in the mortality risk between both species. Fig 2 shows
the Kaplan Meier plot for cumulative survival stratified by ESBL-E species in relation to length
of stay after onset of sepsis.
Discussion
In this study ESBL-KP-Bac bacteremia was associated with different origin, with sepsis with
organ failure and younger age compared to ESBL-EC-Bac cases (S1 Table). Our results under-
line the findings of previous studies showing that K. pneumoniae infections are associated with
more serious illness than E. coli infections [4, 6, 7, 22]. Even though K. pneumoniae bacteremia
was not associated with delayed adequate anti-infective treatment it was associated with
slightly increased mortality, but it did not reach the significance level. The small sub-cohort of
ESBL-KP-Bac might explain this.
Several studies show that a delay of adequate antimicrobial chemotherapy is a risk factor for
in-hospital death [1, 2, 4]. In our cohort, the association of sepsis with organ failure and
reduced DAT demonstrate most likely the realization of the German sepsis guidelines [23].
Patients who present with severe sepsis or septic shock are recommended to be immediately
initiated with an early initial broad-spectrum treatment including reserve antibiotics e.g. carba-
penems. In our study, the presentation of severe sepsis happened before the initiation of the
antimicrobial therapy. Hence, the observed association between disease severity and reduced
DAT represents the response to the severity of the disease and not the cause of the disease. This
refers to the observation that in sepsis with organ failure, an early effective antimicrobial ther-
apy is associated with significantly reduced mortality risk [24]. Even though most cases of sep-
sis with organ failure received appropriate antimicrobial therapy within the first day, more
than 25% showed a DAT of more than 1 day. This observation might at least partly explain the
remaining high mortality (51.9%) in patients with severe sepsis and septic shock.
Table 1. (Continued)
Parameter Bacteremia (n = 138) Sepsis with organ failure (n = 81) P-value
Cancer/immunological disease 63 (45.7%) 24 (29.6%) 0.022*
Continuous parameter are displayed as median (interquartile range), categorical parameter as number (percentage). ESBL, extended-spectrum beta-
lactamase.
*, parameter was included in the multivariable analysis on risk factors for severe sepsis.
doi:10.1371/journal.pone.0158039.t001
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Table 2. Univariate analysis of survivors and non-survivors after ESBL-E sepsis
Univariate analysis
Parameter Survived (n = 165) Deceased (n = 54) P-value
Age years / Age < 61 years 80 (48.5%) 29 (53.7%) 0.534
Male sex 107 (64.8%) 39 (72.2%) 0.406
Charlson comorbidity index > 6 5 (3; 8) 8 (6; 10) <0.001
Days from admission to onset 5 (1; 18) 27 (15; 24) <0.001
Days from onset to discharge/death 14 (9; 26) 12 (2; 31) 0.504
Polymicrobial bacteremia 23 (13.9%) 6 (11.1%) 0.817
Hospital onset 89 (53.9%) 44 (81.5%) <0.001*
ESBL colonization before onset 106 (64.2%) 32 (59.3%) 0.520
Bacteraemia due to E. coli 122 (73.9%) 38 (70.4%) 0.601
Bacteraemia due to K. pneumoniae 43 (26.1%) 16 (29.6%)
Origin of ESBL-E bacteraemia
Urinary tract infection 66 (40.0%) 9 (16.7%) 0.002*
Lower respiratory tract infection 24 (14.5%) 16 (29.6%) 0.024*
Intra-abdominal infection 11 (6.7%) 11 (20.4%) 0.007*
Surgical site infection 4 (2.4%) 4 (7.4%) 0.105*
Primary bacteraemia 10 (6.0%) 20 (37.0%) <0.001*
Other 8 (4.8%) - 0.199
Unknown Origin 44 (26.7%) 12 (22.2%) 0.647
Severity of illness and delay of anti-infective treatment
Bacteremia/ sepsis 126 (76.4%) 12 (22.2%) <0.001*
Severe sepsis/ septic shock 39 (23.6%) 42 (77.8%)
Delayed anti-infective treatment (days) 1 (0;3) 1 (0;2) 0.028*
ESBL Genotype
No ESBL genotype 6 (3.6%) 1 (1.9%) 1.000
CTX-M-1 31 (18.8%) 8 (14.8%) 0.682
CTX-M-14 11 (6.7%) 3 (5.6%) 1.000
CTX-M-15 71 (43.0%) 27 (50.0%) 0.431
CTX-M-2 1 (0.6%) - 1.000
CTX-M-2/97 2 (1.2%) - 1.000
CTX-M-3 6 (3.6%) - 0.340
CTX-M-32 - 2 (3.7%) 0.060
CTX-M-55 1 (0.6%) 1 (1.9%) 0.433
CTX-M-61 1 (0.6%) - 1.000
SHV-12 2 (1.2%) - 1.000
SHV-2 1 (0.6%) - 1.000
SHV-5 9 (5.5%) 4 (7.4%) 0.740
SHV-7 1 (0.6%) - 1.000
TEM-12 1 (0.6%) - 1.000
TEM-52 3 (1.8%) 1 (1.9%) 1.000
Unknown (not available for genotype analysis) 18 (10.9%) 7 (13.0%) 0.631
Underlying conditions
Heart disease 19 (11.5%) 20 (37%) >0.001*
Vascular disease 30 (18.2%) 15 (27.8%) 0.173*
Neurologic disease 18 (10.9%) 3 (5.6%) 0.299
Chronic pulmonary disease 24 (14.5%) 12 (22.2%) 0.206
Connective tissue disease 3 (1.8%) - 1.000
(Continued)
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ESBL-KP-Bac cases were associated with sepsis with organ failure. However, they did not
show significant differences in comorbidities compared to ESBL-EC-Bac cases (S1 Table). This
might be explained by a potentially higher virulence of K. pneumoniae compared to E. coli. An
earlier study on length of hospital stay included parts of the data at hand. Altogether 1.851
cases of bacteremia with (ESBL-positive and–negative) Enterobacteriaceae were analyzed then
[10]. In that study, K. pneumoniae cases were associated with significantly prolonged hospital
stay compared to E. coli cases. This most likely indicates a more problematic course of infection
in K. pneumoniae cases. However, in that former study no data on antimicrobial therapy was
analyzed [10]. Our present results support the previous findings after adjustment for timely
and adequate antimicrobial therapy.
Table 2. (Continued)
Univariate analysis
Parameter Survived (n = 165) Deceased (n = 54) P-value
Ulcer disease 5 (3.0%) 3 (5.6%) 0.411
Liver disease 20 (12.1%) 21 (38.9%) >0.001*
Diabetes mellitus 36 (21.8%) 18 (33.3%) 0.103*
Moderate to severe renal disease 61 (37.0%) 45 (83.3%) >0.001*
Cancer/immunological disease 66 (40.0%) 21 (38.9%) 1.000
Continuous parameter are displayed as median (interquartile range), categorical parameter as number (percentage). ESBL, extended-spectrum beta-
lactamase.
*, parameter was included in the Cox regression analysis on risk factors for death.
doi:10.1371/journal.pone.0158039.t002
Table 3. Results of the multivariable binary logistic regression analysis on risk factors for sepsis with
organ failure
Parameter P-value OR Upper—Lower CI 95
Moderate to severe renal disease <0.001 6.835 3,485–13,405
Liver disease 0.004 3.347 1,463–7,658
Bacteremia due to E.coli <0.001 1 = reference
Bacteremia due to K. pneumoniae 4.499 2,168–9,337
OR, odds ratio. CI 95, 95% conﬁdence interval.
doi:10.1371/journal.pone.0158039.t003
Table 4. Results of the Cox-proportional hazard regression on clinical risk factors for death after
ESBL-E sepsis.
Parameter P-value HR Upper—Lower CI 95
Bacteremia due to E.coli 0.060 1 = reference
Bacteremia due to K. pneumoniae 1.801 0.975–3.330
Urinary tract infection 0.007 0.360 0.172–0.754
Bacteremia/sepsis <0.001 1 = reference
Severe sepsis/ septic shock 4.543 2.134–9.673
Liver disease 0.045 1.801 1.013–3.203
Moderate/ severe renal disease 0.016 2.675 1.198–5.973
HR, hazard ratio. CI 95, 95% conﬁdence interval.
doi:10.1371/journal.pone.0158039.t004
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The primary source of bacteremia differed significantly between both pathogens. While E.
coli bacteremia was mostly found secondary to a urinary tract infection, K. pneumoniae cases
were associated with surgical site infection (SSI), lower respiratory tract infection (LRTI) and
unknown origin. Besides undetected colonization, the latter could be explained by health-care
associated transmission. However, all sites of origin (SSI, LRTI and transmission) are likely
since K. pneumoniae is often identified as outbreak pathogen [25, 26] and shows higher trans-
mission potential than E. coli [27].
Urinary tract infection (UTI) as possible source of bacteremia was found less often associ-
ated with the development of a fatal bacteremia. This goes along with former studies on
ESBL-E bacteremia [7, 28]. ESBL-E are common pathogens of urinary tract infections. A prior
microbiologically diagnosed ESBL-E UTI might have supported an early initiation of anti-
infective treatment at presentation of a secondary bacteremia.
Even though there are significant differences in the ESBL genotype distribution of both
pathogens, none of these genotypes was associated with increased mortality. However, our data
confirms that the most common genotypes among clinical ESBL-positive E. coli isolates in the
United States and in Europe are currently CTX-M-15 and CTX-M-14 [29, 30]. In our K.
Fig 2. Kaplan Meier plot for cumulative survival associated with length of stay after onset of bacteremia
stratified by infecting organism ESBL-positive -E. coli vs. -K. pneumoniae.
doi:10.1371/journal.pone.0158039.g002
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pneumoniae isolates the most common ESBL genotypes were CTX-M-15 and SHV-5 which is
also commonly observed in Europe [3, 31].
In our study, most of the isolates were reported resistant against piperacillin-tazobactam
(pip-taz) due to their ESBL positivity. In 2011, CLSI recommended the interpretation of the
breakpoint should be reported as found, irrespective of whether there was ESBL production
[32]. Based on the current CLSI breakpoints, 35.2% of our isolates would be resistant to pip-
taz. However, in this study, we focused on the results of the treatment based on the reported
antibiogram. This goes along with the observed antimicrobial treatment showing carbapenems
as mostly used agent, followed by quinolones.
This study has limitations. It was performed retrospectively and only ESBL-positive infec-
tions were assessed. Potential differences to ESBL-negative infections cannot be determined.
The study was conducted at a single center. However, the data were collected from all patients
within our hospital, regardless the respective department and likely represents the current
course of these kind of infections in comparable hospitals. The species identification was per-
formed using the Vitek 2 system. Since Vitek 2 cannot differentiate K. pneumoniae and K. var-
iicola, it is possible that up to 10% of our analyzed K. pneumoniae isolates are K. variicola.
Future studies on carbapenem resistance should include ertapenem. Some isolates produce
weak carbapenemases and may show decreased susceptibility to this substance only.
In conclusion, ESBL-positive K. pneumoniae bacteremia compared to ESBL-positive E. coli
bacteremia is often associated with complicated infection and less often with uncomplicated
infection such as urinary tract infection. In this small study group, pathogen on species level
and genotypes were not associated with mortality, but with well-known factors as sepsis with
organ failure. Knowledge of colonization and source of infection should be considered for
empiric anti-infective treatment, especially in patients with septic shock to reduce DAT and
mortality. Infections with ESBL-positive K. pneumoniae should be considered as more serious
infections than comparable E. coli infections. Treatment and prevention strategies should be
adjusted accordingly.
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